The EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trial, the MERIT‐HF (Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure) trial, and the PARADIGM‐HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin‐Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial all manifested similar cardiovascular outcomes in HF patients, with no significant differences between the ischemic and non-ischemic subgroups [22–24]. The gene discussed is ACE; the disease is heart failure.